1
|
Liu RZ, Hu YJ, Wang TF, Yu JC, Wang YX, Zhang YL, Yu M, Zhao B. A novel recombinant human microplasminogen induced complete posterior vitreous detachment without morphological change of retina in juvenile rabbits. Exp Eye Res 2023; 230:109465. [PMID: 37030582 DOI: 10.1016/j.exer.2023.109465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Revised: 03/29/2023] [Accepted: 04/03/2023] [Indexed: 04/08/2023]
Abstract
Vitreomacular traction syndrome results from persistent vitreoretinal adhesions in the setting of partial posterior vitreous detachment (PVD). Vitrectomy and reattachment of retina is an effective therapeutic approach. The adhesion between vitreous cortex and internal limiting membrane (ILM) of the retina is stronger in youth, which brings difficulties to induce PVD in vitrectomy. Several clinical investigations demonstrated that intravitreous injection of plasmin before vitrectomy could reduce the risk of detachment. In our study, a novel recombinant human microplasminogen (rhμPlg) was expressed by Pichia pastoris. Molecular docking showed that the binding of rhμPlg with tissue plasminogen activator (t-PA) was similar to plasminogen, suggesting rh μPlg could be activated by t-PA to generate microplasmin (μPlm). Moreover, rhμPlg had higher catalytic activity than plasminogen in amidolytic assays. Complete PVD was found at vitreous posterior pole of 125 μg rhμPlg-treated eyes without morphological change of retina in juvenile rabbits via intraocular injection. Our results demonstrate that rhμPlg has a potential value in the treatment of vitreoretinopathy.
Collapse
|
2
|
Alsayejh B, Kietsiriroje N, Almutairi M, Simmons K, Pechlivani N, Ponnambalam S, Ajjan RA. Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target. TH OPEN 2022; 6:e396-e407. [PMID: 36452200 PMCID: PMC9674435 DOI: 10.1055/a-1957-6817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2022] [Accepted: 09/23/2022] [Indexed: 11/21/2022] Open
Abstract
The vascular obstructive thrombus is composed of a mesh of fibrin fibers with blood cells trapped in these networks. Enhanced fibrin clot formation and/or suppression of fibrinolysis are associated with an increased risk of vascular occlusive events. Inhibitors of coagulation factors and activators of plasminogen have been clinically used to limit fibrin network formation and enhance lysis. While these agents are effective at reducing vascular occlusion, they carry a significant risk of bleeding complications. Fibrin clot lysis, essential for normal hemostasis, is controlled by several factors including the incorporation of antifibrinolytic proteins into the clot. Plasmin inhibitor (PI), a key antifibrinolytic protein, is cross-linked into fibrin networks with higher concentrations of PI documented in fibrin clots and plasma from high vascular risk individuals. This review is focused on exploring PI as a target for the prevention and treatment of vascular occlusive disease. We first discuss the relationship between the PI structure and antifibrinolytic activity, followed by describing the function of the protein in normal physiology and its role in pathological vascular thrombosis. Subsequently, we describe in detail the potential use of PI as a therapeutic target, including the array of methods employed for the modulation of protein activity. Effective and safe inhibition of PI may prove to be an alternative and specific way to reduce vascular thrombotic events while keeping bleeding risk to a minimum. Key Points Plasmin inhibitor (PI) is a key protein that inhibits fibrinolysis and stabilizes the fibrin network.This review is focused on discussing mechanistic pathways for PI action, role of the molecule in disease states, and potential use as a therapeutic target.
Collapse
Affiliation(s)
- Basmah Alsayejh
- Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, Leeds, United Kingdom
- Ministry of Education, Riyadh, Kingdom of Saudi Arabia
| | - Noppadol Kietsiriroje
- Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, Leeds, United Kingdom
- Endocrinology and Metabolism Unit, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla, Thailand
| | - Mansour Almutairi
- Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, Leeds, United Kingdom
- General Directorate of Medical Services, Ministry of Interior, Kingdom of Saudi Arabia
| | - Katie Simmons
- Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, Leeds, United Kingdom
| | - Nikoletta Pechlivani
- Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, Leeds, United Kingdom
| | - Sreenivasan Ponnambalam
- School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, UK
| | - Ramzi A. Ajjan
- Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, Leeds, United Kingdom
| |
Collapse
|
3
|
Fibrinolytic nanocages dissolve clots in the tumor microenvironment, improving the distribution and therapeutic efficacy of anticancer drugs. Exp Mol Med 2021; 53:1592-1601. [PMID: 34667244 PMCID: PMC8569170 DOI: 10.1038/s12276-021-00688-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Revised: 08/30/2021] [Accepted: 08/31/2021] [Indexed: 12/12/2022] Open
Abstract
Fibrin, one of the components of the extracellular matrix (ECM), acts as a transport barrier within the core of tumors by constricting the blood vessels and forming clots, leading to poor intratumoral distribution of anticancer drugs. Our group previously developed a microplasmin-based thrombolytic ferritin nanocage that efficiently targets and dissolves clots without causing systemic fibrinolysis or disrupting hemostatic clots. We hypothesized that the thrombolytic nanocage-mediated degradation of fibrin clots in the tumor ECM can lead to enhanced intratumoral drug delivery, especially for nanosized anticancer drugs. Fibrin clot deposition worsens after surgery and chemotherapy, further hindering drug delivery. Moreover, the risk of venous thromboembolism (VTE) also increases. Here, we used thrombolytic nanocages with multivalent clot-targeting peptides and fibrin degradation enzymes, such as microplasmin, to dissolve fibrin in the tumor microenvironment and named them fibrinolytic nanocages (FNCs). These FNCs target tumor clots specifically and effectively. FNCs efficiently dissolve fibrin clots inside of the tumor vessels, suggesting that they can mitigate the risk of VTE in cancer patients. Coadministration of FNC and doxorubicin led to improved chemotherapeutic activity in a syngeneic mouse melanoma model. Furthermore, the FNCs increased the distribution of Doxil/doxorubicin nanoparticles within mouse tumors. These results suggest that fibrinolytic cotherapy might help improve the therapeutic efficacy of anticancer nanomedicines. Thus, microplasmin-based fibrinolytic nanocages are promising candidates for this strategy due to their hemostatic safety and ability to home in on the tumor.
Collapse
|
4
|
Baghban R, Farajnia S, Ghasemi Y, Mortazavi M, Samadi N, Zarghami N. Assessment of E. coli Expression System for Overexpression of Active Recombinant Ocriplasmin. Adv Pharm Bull 2021; 11:564-569. [PMID: 34513632 PMCID: PMC8421613 DOI: 10.34172/apb.2021.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 04/24/2020] [Accepted: 06/21/2020] [Indexed: 11/23/2022] Open
Abstract
Purpose: Ocriplasmin (Jetrea TM) is a FDA approved recombinant enzyme utilized in the treatment of vitreomacular adhesion (VMA). This is a recombinant C-terminal fragment of human plasmin produced using yeast Pichia pastoris. Since ocriplasmin does not contain any Oor N-glycosylation or some other post-translational modifications, bacterial expression systems such as Escherichia coli could be considered as an economical host for recombinant expression. In the present study, we aimed to evaluate the efficiency of E. coli expression system for highlevel expression of recombinant ocriplasmin. Methods: The gene coding for ocriplasmin was cloned and expressed in E. coli BL21. The bacterial cells were cultured on large scale and the expressed recombinant protein was purified using Ni-NTA chromatography. Refolding of denatured ocriplasmin to active enzyme was carried out by the stepwise removal of denaturant. The identity of recombinant ocriplasmin was confirmed using western blotting and ELISA assays. The presence of the active ocriplasmin was monitored by the hydrolytic activity assay against the chromogenic substrate S-2403. Results: The final yield of E. coli BL21-produced ocriplasmin was approximately 1 mg/mL which was greater than that of P. pastoris. Using western blotting and ELISA assay, the identity of recombinant ocriplasmin was confirmed. The hydrolysis of chromogenic substrate S-2403 verified the functional activity of E. coli produced ocriplasmin. Conclusion: The results of this study indicated that E. coli could be used for high level expression of ocriplasmin. Although the recombinant protein was expressed as inclusion body, the stepwise refolding leads to the biologically active proteins.
Collapse
Affiliation(s)
- Roghayyeh Baghban
- Medical Biotechnology Department, Faculty of Advanced Medical Science, Tabriz University of Medical Sciences,Tabriz, Iran.,Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.,Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.,Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Safar Farajnia
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.,Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Younes Ghasemi
- Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Shiraz University of Medical Science, Shiraz, Iran
| | - Mojtaba Mortazavi
- Department of Biotechnology, Institute of Science and High Technology and Environmental Science, Graduate University of Advanced Technology, Kerman, Iran
| | - Naser Samadi
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Nosratollah Zarghami
- Medical Biotechnology Department, Faculty of Advanced Medical Science, Tabriz University of Medical Sciences,Tabriz, Iran
| |
Collapse
|
5
|
Cioni P, Gabellieri E, Campanini B, Bettati S, Raboni S. Use of Exogenous Enzymes in Human Therapy: Approved Drugs and Potential Applications. Curr Med Chem 2021; 29:411-452. [PMID: 34259137 DOI: 10.2174/0929867328666210713094722] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 03/05/2021] [Accepted: 03/17/2021] [Indexed: 11/22/2022]
Abstract
The development of safe and efficacious enzyme-based human therapies has increased greatly in the last decades, thanks to remarkable advances in the understanding of the molecular mechanisms responsible for different diseases, and the characterization of the catalytic activity of relevant exogenous enzymes that may play a remedial effect in the treatment of such pathologies. Several enzyme-based biotherapeutics have been approved by FDA (the U.S. Food and Drug Administration) and EMA (the European Medicines Agency) and many are undergoing clinical trials. Apart from enzyme replacement therapy in human genetic diseases, which is not discussed in this review, approved enzymes for human therapy find applications in several fields, from cancer therapy to thrombolysis and the treatment, e.g., of clotting disorders, cystic fibrosis, lactose intolerance and collagen-based disorders. The majority of therapeutic enzymes are of microbial origin, the most convenient source due to fast, simple and cost-effective production and manipulation. The use of microbial recombinant enzymes has broadened prospects for human therapy but some hurdles such as high immunogenicity, protein instability, short half-life and low substrate affinity, still need to be tackled. Alternative sources of enzymes, with reduced side effects and improved activity, as well as genetic modification of the enzymes and novel delivery systems are constantly searched. Chemical modification strategies, targeted- and/or nanocarrier-mediated delivery, directed evolution and site-specific mutagenesis, fusion proteins generated by genetic manipulation are the most explored tools to reduce toxicity and improve bioavailability and cellular targeting. This review provides a description of exogenous enzymes that are presently employed for the therapeutic management of human diseases with their current FDA/EMA-approved status, along with those already experimented at the clinical level and potential promising candidates.
Collapse
Affiliation(s)
- Patrizia Cioni
- Institute of Biophysics, National Research Council, Via Moruzzi 1, 56124 Pisa. Italy
| | - Edi Gabellieri
- Institute of Biophysics, National Research Council, Via Moruzzi 1, 56124 Pisa. Italy
| | - Barbara Campanini
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 23/A, 43124 Parma. Italy
| | - Stefano Bettati
- Institute of Biophysics, National Research Council, Via Moruzzi 1, 56124 Pisa. Italy
| | - Samanta Raboni
- Institute of Biophysics, National Research Council, Via Moruzzi 1, 56124 Pisa. Italy
| |
Collapse
|
6
|
Singh S, Saleem S, Reed GL. Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease. Front Cardiovasc Med 2020; 7:608899. [PMID: 33426005 PMCID: PMC7785519 DOI: 10.3389/fcvm.2020.608899] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Accepted: 12/02/2020] [Indexed: 01/23/2023] Open
Abstract
Alpha2-antiplasmin (α2AP), the fast-reacting, serine protease inhibitor (serpin) of plasmin, was originally thought to play a key role in protection against uncontrolled, plasmin-mediated proteolysis of coagulation factors and other molecules. However, studies of humans and mice with genetic deficiency of α2AP have expanded our understanding of this serpin, particularly in disease states. Epidemiology studies have shown an association between high α2AP levels and increased risk or poor outcome in cardiovascular diseases. Mechanistic studies in disease models indicate that α2AP stops the body's own fibrinolytic system from dissolving pathologic thrombi that cause venous thrombosis, pulmonary embolism, arterial thrombosis, and ischemic stroke. In addition, α2AP fosters the development of microvascular thrombosis and enhances matrix metalloproteinase-9 expression. Through these mechanisms and others, α2AP contributes to brain injury, hemorrhage and swelling in experimental ischemic stroke. Recent studies also show that α2AP is required for the development of stasis thrombosis by inhibiting the early activation of effective fibrinolysis. In this review, we will discuss the key role played by α2AP in controlling thrombosis and fibrinolysis and, we will consider its potential value as a therapeutic target in cardiovascular diseases and ischemic stroke.
Collapse
Affiliation(s)
- Satish Singh
- Department of Medicine, University of Arizona-College of Medicine, Phoenix, AZ, United States
| | - Sofiyan Saleem
- Department of Medicine, University of Arizona-College of Medicine, Phoenix, AZ, United States
| | - Guy L Reed
- Department of Medicine, University of Arizona-College of Medicine, Phoenix, AZ, United States
| |
Collapse
|
7
|
Kaur N, Sinha PK, Sahni G. Site-specific PEGylation of micro-plasmin for improved thrombolytic therapy through engineering enhanced resistance against serpin mediated inhibition. PLoS One 2019; 14:e0217234. [PMID: 31141522 PMCID: PMC6541275 DOI: 10.1371/journal.pone.0217234] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2019] [Accepted: 05/08/2019] [Indexed: 12/03/2022] Open
Abstract
The relatively rapid inhibition of microplasmin by α2-AP leads to short functional half-life of the molecule in vivo, causing inefficient clot dissolution, even after site-specific, local catheter-based delivery. Here, we describe a PEGylation approach for improving the therapeutic potential via improving the survival of microplasmin in presence of its cognate inhibitor, α2-AP, wherein a series of strategically designed cysteine analogs of micro-plasminogen were prepared and expressed in E. coli, and further modified by covalent grafting in vitro with PEG groups of different molecular sizes so as to select single or double PEG chains that increase the molecular weight and hydrodynamic radii of the conjugates, but with a minimal discernible effect on intrinsic plasmin activity and structural framework, as explored by amidolytic activity and CD-spectroscopy, respectively. Interestingly, some of the purified PEG-coupled proteins after conversion to their corresponding proteolytically active forms were found to exhibit significantly reduced inhibition rates (up to 2-fold) by α2-AP relative to that observed with wild-type microplasmin. These results indicate an interesting, and not often observed, effect of PEG groups through reduced/altered dynamics between protease and inhibitor, likely through a steric hindrance mechanism. Thus, the present study successfully identifies single- and double-site PEGylated muteins of microplasmin with significantly enhanced functional half-life through enhanced resistance to inactivation by its in vivo plasma inhibitor. Such an increased survival of bioactivity in situ, holds unmistakable potential for therapeutic exploitation, especially in ischemic strokes where a direct, catheter-based deposition within the cranium has been shown to be promising, but is currently limited by the very short in vivo bioactive half-life of the fibrin dissolving agent/s.
Collapse
Affiliation(s)
- Navneet Kaur
- CSIR-Institute of Microbial Technology, Chandigarh, India
- Panjab University, Chandigarh, India
| | - Prakash Kumar Sinha
- CSIR-Institute of Microbial Technology, Chandigarh, India
- Panjab University, Chandigarh, India
| | - Girish Sahni
- CSIR-Institute of Microbial Technology, Chandigarh, India
- * E-mail:
| |
Collapse
|
8
|
Joison A, Baiardi G, Donalisio R, Gallo F. Fibrinolytic Activity of Two Polypeptide Chains from Human Plasminogen#. CURR PROTEOMICS 2019. [DOI: 10.2174/1570164616666190112120215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Plasminogen is a blood plasma glycoprotein of molecular weight about
92,000 Daltons. Physiologically, it incorporates into blood clots and after its activation by plasminogen
activators to plasmin can perform a fibrinolytic function. Microplasmin is truncate polypeptide chain
derivate of plasmin may be increase the fibrinolytic activity.
Objective:
To study the amino acid sequence of two polypeptides chains derivate to the plasminogen
with fibrinolytic activity.
Methods:
he two polypeptides chains were prepared by isoelectric precipitation of human plasma in
sodium borate buffer. The sample in a second step was subjected to affinity and ionic interchange
chromatography and denaturalized electrophoresis was carried out on the sample previous heat 70ºC.
Results:
Two polypeptide chains of 29.000 and 35.000 Daltons by autolysis controlled were obtained
with 25 UI of fibrinolytic activity in fibrin plate.
Conclusion:
Microplasmin was obtained with cleavage in different amino acid bounds and rearrangement
of amino acids by autolysis with controlled alkaline precipitation.
Collapse
Affiliation(s)
- Agustín Joison
- School of Chemistry, Catholic University of Cordoba, Cordoba, Argentina
| | - Gustavo Baiardi
- Institute of Biological and Technological Research (IIBYT-CONICET), National University of Cordoba, School of Chemistry, Catholic University of Cordoba, Cordoba, Argentina
| | - Rocío Donalisio
- Institute of Biological and Technological Research (IIBYT-CONICET), National University of Cordoba, School of Chemistry, Catholic University of Cordoba, Cordoba, Argentina
| | - Federico Gallo
- Institute of Vascular Research, Viedma 493, CP 8332 General Roca, Río Negro, Argentina
| |
Collapse
|
9
|
Fibrinolytic Enzymes for Thrombolytic Therapy. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2019; 1148:345-381. [DOI: 10.1007/978-981-13-7709-9_15] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
10
|
A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2018; 14:633-642. [DOI: 10.1016/j.nano.2017.12.022] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Revised: 12/18/2017] [Accepted: 12/29/2017] [Indexed: 01/08/2023]
|
11
|
Adivitiya, Khasa YP. The evolution of recombinant thrombolytics: Current status and future directions. Bioengineered 2016; 8:331-358. [PMID: 27696935 DOI: 10.1080/21655979.2016.1229718] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Cardiovascular disorders are on the rise worldwide due to alcohol abuse, obesity, hypertension, raised blood lipids, diabetes and age-related risks. The use of classical antiplatelet and anticoagulant therapies combined with surgical intervention helped to clear blood clots during the inceptive years. However, the discovery of streptokinase and urokinase ushered the way of using these enzymes as thrombolytic agents to degrade the fibrin network with an issue of systemic hemorrhage. The development of second generation plasminogen activators like anistreplase and tissue plasminogen activator partially controlled this problem. The third generation molecules, majorly t-PA variants, showed desirable properties of improved stability, safety and efficacy with enhanced fibrin specificity. Plasmin variants are produced as direct fibrinolytic agents as a futuristic approach with targeted delivery of these drugs using liposome technlogy. The novel molecules from microbial, plant and animal origin present the future of direct thrombolytics due to their safety and ease of administration.
Collapse
Affiliation(s)
- Adivitiya
- a Department of Microbiology , University of Delhi South Campus , New Delhi , India
| | - Yogender Pal Khasa
- a Department of Microbiology , University of Delhi South Campus , New Delhi , India
| |
Collapse
|
12
|
de Smet MD, Stassen JM, Meenink TCM, Janssens T, Vanheukelom V, Naus GJL, Beelen MJ, Jonckx B. Release of experimental retinal vein occlusions by direct intraluminal injection of ocriplasmin. Br J Ophthalmol 2016; 100:1742-1746. [PMID: 27688592 PMCID: PMC5256413 DOI: 10.1136/bjophthalmol-2016-309190] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Revised: 08/25/2016] [Accepted: 09/03/2016] [Indexed: 12/13/2022]
Abstract
PURPOSE Retinal vein occlusions (RVO) are a major cause of vision loss in people aged 50 years and older. Current therapeutic options limit the consequences of RVO but do not eliminate the cause. Cannulation of the involved vessel and removal of the clot may provide a more permanent solution with a less demanding follow-up. However, cannulation of smaller retinal veins remains challenging. This paper explores the use of ocriplasmin (recombinant plasmin without its kringles) to clear RVO, using a robotic micromanipulator. METHODS Branch RVO were induced in a porcine model with rose bengal followed by 532 nm endolaser to the superior venous branch of the optic nerve. The vein was cannulated proximal to the occlusion or beyond the first branching vessel from the obstruction. The vein was infused with a physiologic citric acid buffer solution (CAM) or CAM/ocriplasmin. The time of cannulation, number of attempts, and the ability to release the thrombus were recorded. RESULTS Cannulation and infusion was possible in all the cases. The use of a micromanipulator allowed for a consistent cannulation of the retinal vein and positional stability allowed the vein to remain cannulated for up to 20 min. In none of the attempts (5/5) with CAM did the thrombus dissolve, despite repeat infusion/relaxation cycles. In 7/7 injections of CAM/ocriplasmin near to the point of obstruction, the clot started to dissolve within a few minutes of injection. An infusion, attempted beyond the first venous branch point proximal to the clot, was unsuccessful in 2/3 attempts. CONCLUSIONS Ocriplasmin is effective in resolving RVO if injected close to the site of occlusion with the use of a micromanipulator.
Collapse
Affiliation(s)
- Marc D de Smet
- MicroInvasive Ocular Surgery Center (MIOS sa), Lausanne, Switzerland.,Preceyes nv, Eindhoven, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Chuang CC, Chen SN. Induction of Posterior Vitreous Detachment in Pediatric Vitrectomy by Preoperative Intravitreal Injection of Tissue Plasminogen Activator. J Pediatr Ophthalmol Strabismus 2016; 53:113-8. [PMID: 27018884 DOI: 10.3928/01913913-20160209-01] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2015] [Accepted: 01/01/2016] [Indexed: 11/20/2022]
Abstract
PURPOSE To report the efficacy of intravitreal injection of tissue plasminogen activator (tPA) with or without autoserum in induction of posterior vitreous detachment (PVD) in pediatric vitrectomy. METHODS Retrospective, interventional case series of pediatric patients receiving intravitreal injection of tPA preoperatively to facilitate PVD in vitrectomy from January 2011 to December 2014 at the Changhua Christian Hospital, Taiwan. All patients received intravitreal injections of 25 µg of tPA 3 days before vitrectomy. For cases without preexisting vitreous hemorrhage, 0.1 mL of intravitreal autologous serum was co-administered. Main outcome measures included successful rate of posterior vitreous detachment in vitrectomy, visual outcome, and related ocular complications. RESULTS Four boys and 2 girls were included. Ages ranged from 39 weeks' postmenstrual age to 8 years. The indications for vitrectomy were traumatic macular hole (cases 1 and 2); premacular hemorrhage secondary to retinopathy of prematurity (case 3); abusive head trauma with premacular hemorrhage, subinternal limiting membrane hemorrhage, and macular hole (case 4); trauma with dense vitreous hemorrhage (case 5); and vitreous hemorrhage with unknown cause (case 6). Successful PVD was induced intraoperatively in all cases and the macular hole was closed successfully in 3 of 3 cases (cases 1, 2, and 4). No surgical complications were noted. Visual outcome improved in all 3 eyes with checkable preoperative visual acuity (cases 1, 2, and 6). CONCLUSIONS Intravitreal injection of tPA 3 days before vitrectomy may be a helpful adjunct to induce pediatric PVD.
Collapse
|
14
|
In vitro fibrinolysis and antithrombosis characterizations of novel recombinant microplasminogen with RGD and GPRP peptides. J Thromb Thrombolysis 2016; 42:118-26. [DOI: 10.1007/s11239-016-1334-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Abstract
Research and drug developments fostered under orphan drug product development programs have greatly assisted the introduction of efficient and safe enzyme-based therapies for a range of rare disorders. The introduction and regulatory approval of 20 different recombinant enzymes has enabled, often for the first time, effective enzyme-replacement therapy for some lysosomal storage disorders, including Gaucher (imiglucerase, taliglucerase, and velaglucerase), Fabry (agalsidase alfa and beta), and Pompe (alglucosidase alfa) diseases and mucopolysaccharidoses I (laronidase), II (idursulfase), IVA (elosulfase), and VI (galsulfase). Approved recombinant enzymes are also now used as therapy for myocardial infarction (alteplase, reteplase, and tenecteplase), cystic fibrosis (dornase alfa), chronic gout (pegloticase), tumor lysis syndrome (rasburicase), leukemia (L-asparaginase), some collagen-based disorders such as Dupuytren's contracture (collagenase), severe combined immunodeficiency disease (pegademase bovine), detoxification of methotrexate (glucarpidase), and vitreomacular adhesion (ocriplasmin). The development of these efficacious and safe enzyme-based therapies has occurred hand in hand with some remarkable advances in the preparation of the often specifically designed recombinant enzymes; the manufacturing expertise necessary for commercial production; our understanding of underlying mechanisms operative in the different diseases; and the mechanisms of action of the relevant recombinant enzymes. Together with information on these mechanisms, safety findings recorded so far on the various adverse events and problems of immunogenicity of the recombinant enzymes used for therapy are presented.
Collapse
|
16
|
Liu R, Zhao B, Zhang Y, Gu J, Yu M, Song H, Yu M, Mo W. High-level expression, purification, and enzymatic characterization of truncated human plasminogen (Lys531-Asn791) in the methylotrophic yeast Pichia pastoris. BMC Biotechnol 2015; 15:50. [PMID: 26054637 PMCID: PMC4460660 DOI: 10.1186/s12896-015-0179-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2015] [Accepted: 06/01/2015] [Indexed: 01/28/2023] Open
Abstract
Background Plasmin is a serine protease that plays a critical role in fibrinolysis, which is a process that prevents blood clots from growing and becoming problematic. Recombinant human microplasminogen (rhμPlg) is a derivative of plasmin that solely consists of the catalytic domain of human plasmin and lacks the five kringle domains found in the native protein. Developing an industrial production method that provides high yields of this protein with high purity, quality, and potency is critical for preclinical research. Results The human microplasminogen gene was cloned into the pPIC9K vector, and the recombinant plasmid was transformed into Pichia pastoris strain GS115. The concentration of plasmin reached 510.1 mg/L of culture medium. Under fermentation conditions, the yield of rhμPlg was 1.0 g/L. We purified rhμPlg to 96 % purity by gel-filtration and cation-exchange chromatography. The specific activity of rhμPlg reached 23.6 U/mg. The Km of substrate hydrolysis by recombinant human microplasmin was comparable to that of human plasmin, while rhμPlm had higher kcat/Km values than plasmin. The high purity and activity of the rhμPlg obtained here will likely prove to be a valuable tool for studies of its application in thrombotic diseases and vitreoretinopathies. Conclusions Reliable rhμPlg production (for use in therapeutic applications) is feasible using genetically modified P. pastoris as a host strain. The successful expression of rhμPlg in P. pastoris lays a solid foundation for its downstream application. Electronic supplementary material The online version of this article (doi:10.1186/s12896-015-0179-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Rongzeng Liu
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| | - Bing Zhao
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| | - Yanling Zhang
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| | - Junxiang Gu
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| | - Mingrong Yu
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| | - Houyan Song
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Collaborative Innovation Center for Biotherapy, Sichuan University, Huaxi Campus: No.17 People's South Road, Chengdu, 610041, China.
| | - Min Yu
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| | - Wei Mo
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| |
Collapse
|
17
|
Hlavica M, Diepers M, Garcia-Esperon C, Ineichen BV, Nedeltchev K, Kahles T, Remonda L. Pharmacological recanalization therapy in acute ischemic stroke – Evolution, current state and perspectives of intravenous and intra-arterial thrombolysis. J Neuroradiol 2015; 42:30-46. [DOI: 10.1016/j.neurad.2014.11.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2014] [Accepted: 11/07/2014] [Indexed: 10/24/2022]
|
18
|
Abstract
Alteplase, an intravenously administered form of recombinant tissue plasminogen activator (rt-PA), remains the only US FDA-approved thrombolytic treatment for acute ischemic stroke within 3 h of symptom onset. Patients treated with intravenous rt-PA are at least 30% more likely to have minimal or no disability at 3 months compared with placebo. Despite an increased risk of symptomatic intracranial hemorrhage, rt-PA does not increase mortality. The benefit achieved with rt-PA is cost effective and sustained 1 year after treatment. Despite its clear benefit, rt-PA remains underutilized. Although the future of acute ischemic stroke treatment will most likely involve a multi-faceted treatment approach, the primary objective remains to establish recanalization of the involved vessel. For patients with acute ischemic stroke within the first 3 h of symptom onset, rt-PA remains the first step in accomplishing this goal.
Collapse
Affiliation(s)
- Nicole R Gonzales
- University of Texas, Houston Medical School, 6431 Fannin, MSB 7.118, Houston TX 7703, USA.
| | | |
Collapse
|
19
|
Abstract
PURPOSE To discuss the potential role of microplasmin (ocriplasmin) as a surgical adjunct to vitrectomy in pediatric vitreoretinopathies. METHODS Literature review of the laboratory and clinical evidence to date for the use of both autologous plasmin enzyme as an adjunct to vitrectomy and more recently recombinant microplasmin (ocriplasmin) as monotherapy for focal vitreomacular traction in adults. RESULTS Autologous plasmin enzyme is currently being used as a surgical adjunct to vitrectomy, with supporting Levels 2 and 3 published evidence in a range of pediatric vitreoretinopathies including Stage 5 retinopathy of prematurity and congenital X-linked retinoschisis. The availability of autologous plasmin enzyme is limited. In recent Phase 3 clinical trials, intravitreal ocriplasmin versus sham injection resulted in resolution of focal vitreomacular traction in 27% versus 10% (P < 0.001, n = 652). CONCLUSION Ocriplasmin may potentially be used as a surgical adjunct to vitrectomy in place of autologous plasmin enzyme. A Phase 2, randomized, placebo-controlled surgical trial is under way to assess this.
Collapse
|
20
|
Lin X, Wang Y, Zhang Y, Huang B, Lin JJ, Hallock SJ, Yu H, Shao H, Yan J, Huang B, Zhang XC, Cao W, Xu X, Lin X. Purification and characterization of mutant miniPlasmin for thrombolytic therapy. Thromb J 2013; 11:2. [PMID: 23363549 PMCID: PMC3724493 DOI: 10.1186/1477-9560-11-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2012] [Accepted: 01/24/2013] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Previous animal studies by us and others have indicated that catheter-administered plasmin or its des-kringle derivatives may be more appropriate alternatives to plasminogen activators for treating thrombolytic diseases, since it has a very short serum half-life and therefore does not result in hemorrhaging. We have previously produced recombinant miniPlasmin (mPlasmin) that was proven suitable for treating peripheral arterial occlusion in animal models. However, our previous results showed that non-specific cleavage at position K698 of mPlasmin during activation hindered the further development of this promising therapeutic candidate. In order to minimize or eliminate the non-specific cleavage problem, we performed saturation mutagenesis at the K698 position to develop a mutant form of mPlasmin for thrombolytic therapy. METHODS We changed K698 to 16 other amino acids, with preferred E. coli codons. Each of these mutants were expressed in E. coli as inclusion bodies and then refolded, purified, and subsequently characterized by detailed kinetic assays/experiments/studies which identified highly active mutants devoid of non-specific cleavage. RESULTS Activation studies indicated that at those conditions in which the wild type enzyme is cut at the non-specific position K698, the active mutants can be activated without being cleaved at this position. CONCLUSIONS From the above results, we selected two mutants, K698Q and K698N, as our lead candidates for further thrombolytic drug developments. The selected mutants are potentially better therapeutic candidates for thrombolytic therapy.
Collapse
Affiliation(s)
- Xiaotao Lin
- Genecopoeia Inc, 9620 Medical Center Drive #101, 20850, Rockville, MD, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Suzuki Y. [Evaluation for antithrombotic agents by a thrombotic model in animals]. YAKUGAKU ZASSHI 2012; 132:1019-24. [PMID: 23023418 DOI: 10.1248/yakushi.132.1019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
To investigate cerebral infarction and intracranial hemorrhage (ICH) in relation to antithrombotic agents, we established an animal stroke model induced by using a combination of a photosensitive dye and local green photoillumination. Microplasmin (μPli), a derivative of plasmin lacking the five "kringle" domains, was administered in this model, and its effect was studied using magnetic resonance imaging. μPli treatment reduced cerebral damage 24 h after middle cerebral artery occlusion; it also reduced the expansion of the positive area on perfusion-weighted images between 1 and 24 h and the degree of neurological deficits. Tissue-type plasminogen activator (t-PA), a serine proteinase that converts plasminogen to plasmin, has been approved for treating acute ischemic stroke, but delayed treatment is associated with increased risk of ICH. Plasmin participates in the degradation of fibrin, causing clot lysis, and of various extracellular matrix proteins, either directly or via the activation of matrix metalloproteinases (MMPs). In this study, we observed that MMP-3 is relatively important in the enhanced risk of ICH induced by delayed t-PA treatment for ischemic stroke. In particular, the binding of t-PA with low-density lipoprotein receptor-related protein (LRP) results in the release of MMP-3 by endothelial cells. LRP production is upregulated in endothelial cells exposed to ischemia, and elevated LRP levels have been implicated in the increased ICH risk associated with delayed t-PA treatment. This implies that the t-PA/LRP/MMP-3 pathway may be a suitable target for developing strategies to improve the therapeutic efficacy of t-PA in acute ischemic stroke.
Collapse
Affiliation(s)
- Yasuhiro Suzuki
- Department of Pharmacology, Hamamatsu University School of Medicine, Shizuoka, Japan.
| |
Collapse
|
22
|
|
23
|
Aerts F, Noppen B, Fonteyn L, Derua R, Waelkens E, de Smet MD, Vanhove M. Mechanism of inactivation of ocriplasmin in porcine vitreous. Biophys Chem 2012; 165-166:30-8. [DOI: 10.1016/j.bpc.2012.03.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2012] [Accepted: 03/01/2012] [Indexed: 01/30/2023]
|
24
|
Flemmig M, Melzig MF. Serine-proteases as plasminogen activators in terms of fibrinolysis. ACTA ACUST UNITED AC 2012; 64:1025-39. [PMID: 22775207 DOI: 10.1111/j.2042-7158.2012.01457.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVES This review should give an overview about the natural human plasminogen activators and their various modified variants as well as similar substances isolated from animals, microorganisms and plants. When a blood clot is formed in a blood vessel, it avoids the oxygen supply of the surrounding tissue. A fast fibrinolytic therapy should redissolve the blood vessel and reduce the degradation of the tissue. All proteases that are part of the human blood coagulation and fibrinolytic system belong to the serine protease family. t-PA (tissue plasminogen activator) and u-PA (urokinase plasminogen activator) are the naturally occurring fibrinolytic agents that are also used in therapy. KEY FINDINGS Despite many years of research, t-PA is still the gold standard in fibrinolytic therapy. But it has to be given as an infusion, which needs time. Modified fibrinolytic substances are, were, or perhaps will be in the market. They have different advantages over t-PA, but often the disadvantages predominate. CONCLUSION Many substances have been developed but an optimal fibrinolytic agent combined with a simple administration is not in therapeutic use to date.
Collapse
Affiliation(s)
- Martin Flemmig
- Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany
| | | |
Collapse
|
25
|
A Clinically Relevant Rabbit Embolic Stroke Model for Acute Ischemic Stroke Therapy Development: Mechanisms and Targets. Transl Stroke Res 2012. [DOI: 10.1007/978-1-4419-9530-8_27] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
26
|
Magnetic purification of plasminogen from human plasma by specific lysine affinity. J Biosci Bioeng 2011; 112:219-24. [DOI: 10.1016/j.jbiosc.2011.05.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2011] [Revised: 05/03/2011] [Accepted: 05/05/2011] [Indexed: 10/18/2022]
|
27
|
Schneider EW, Johnson MW. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin Ophthalmol 2011; 5:1151-65. [PMID: 21887098 PMCID: PMC3162296 DOI: 10.2147/opth.s14840] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2011] [Indexed: 12/18/2022] Open
Abstract
With the dissemination of optical coherence tomography over the past two decades, the role of persistent vitreomacular adhesion (VMA) in the development of numerous macular pathologies - including idiopathic macular hole, vitreomacular traction syndrome, cystoid and diabetic macular edema, neovascularization in diabetic retinopathy and retinal vein occlusion, exudative age-related macular degeneration, and myopic traction maculopathy - has been established. While invasive vitreoretinal procedures have long been utilized to address complications related to these disorders, such an approach is hampered by incomplete vitreoretinal separation and vitreous removal, surgical complications, and high costs. In light of such limitations, investigators have increasingly looked to nonsurgical means for the treatment of persistent pathologic VMA. Chief among these alternative measures is the intravitreal application of pharmacologic agents for the induction of vitreous liquefaction and/or vitreoretinal separation, an approach termed pharmacologic vitreolysis. This article aims to review the available evidence regarding the use of pharmacologic agents in the treatment of VMA-related pathology. In addition, a discussion of vitreous molecular organization and principles of physiologic posterior vitreous detachment is provided to allow for a consideration of vitreolytic agent mode of action and molecular targets.
Collapse
Affiliation(s)
- Eric W Schneider
- Department of Ophthalmology and Visual Sciences, University of Michigan, WK Kellogg Eye Center, Ann Arbor, MI, USA
| | - Mark W Johnson
- Department of Ophthalmology and Visual Sciences, University of Michigan, WK Kellogg Eye Center, Ann Arbor, MI, USA
| |
Collapse
|
28
|
Marder VJ. Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin. J Thromb Haemost 2011; 9 Suppl 1:364-73. [PMID: 21781273 DOI: 10.1111/j.1538-7836.2011.04370.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Two issues have held the focus of thrombolysis research for over 50 years, namely, choosing between a plasminogen activator (PA) or plasmin as the best therapeutic agent and choosing between systemic or local administration. The original plasmin product of the 1950s was both ineffective and contaminated with PA, and catheter technology was not yet developed for routine clinical use. For decades, clinical practice has focused on PA and systemic administration, but today, PAs are often administered by catheter into thrombosed vessels, notably for peripheral arterial and graft occlusion and deep vein thrombosis, and increasingly for acute ischaemic stroke. Despite using catheter-delivered therapy, bleeding complications still occur, most severely expressed as symptomatic intracranial haemorrhage. New experimental data indicate that we should now reconsider plasmin as a viable, even preferable, thrombolytic agent. Plasmin requires catheter delivery to achieve thrombolysis, but this technical issue has been solved with modern technology and widespread presence of interventional suites. After local administration, plasmin will lyse thrombi; thereafter, any plasmin in the circulation will be rapidly neutralised. Pre-clinical studies confirm that plasmin has marked haemostatic safety advantage over t-PA. After more than 50 years, the field has come full circle, and plasmin as the thrombolytic agent and catheter use for local delivery of agent may represent a step forward in thrombolytic therapy.
Collapse
Affiliation(s)
- V J Marder
- Division of Hematology and Medical Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
| |
Collapse
|
29
|
A novel human microplasmin fold: new perspective to thrombosis treatment. Blood Coagul Fibrinolysis 2011; 22:236-9. [DOI: 10.1097/mbc.0b013e3283425498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Paul M, Ma JKC. Plant-made pharmaceuticals: Leading products and production platforms. Biotechnol Appl Biochem 2011; 58:58-67. [DOI: 10.1002/bab.6] [Citation(s) in RCA: 121] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
31
|
Goldenberg DT, Giblin FJ, Cheng M, Chintala SK, Trese MT, Drenser KA, Ruby AJ. Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes. Retina 2011; 31:393-400. [PMID: 21099453 PMCID: PMC3057916 DOI: 10.1097/iae.0b013e3181e586b2] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE Intravitreal bevacizumab (BV) (Avastin, Genentech Inc., South San Francisco, CA) is frequently used for the treatment of age-related macular degeneration. Previous studies have demonstrated full-thickness retinal penetration. Intravitreal recombinant microplasmin (MP) has been shown to successfully induce a posterior vitreous detachment (PVD) and vitreous liquefaction in animals. It has been suggested that a PVD may alter the retinal penetration of molecules in the vitreous cavity. The aim of this study was to compare BV retinal penetration in rabbit eyes with and without an MP-induced PVD. METHODS Twelve adult rabbits were injected with 0.1 mL (0.4 mg) of MP into the vitreous cavity of 1 eye. One week later, the rabbits were injected with 0.05 mL (1.25 mg) of BV into both eyes. Both eyes of 3 rabbits were harvested at 6 hours, 12 hours, 24 hours, and 72 hours after the BV injection. Frozen retinal cross sections were prepared, and BV retinal penetration was evaluated with immunohistochemistry using a fluorescence-labeled antibody against BV. Two eyes from one rabbit were not injected with either agent and used as controls to compare the background autofluorescence. Peripapillary retinal sections were recorded with a digital camera, and intraretinal BV fluorescence-labeled antibody was measured by qualitative photographic interpretation. Two additional rabbits received an intravitreal injection of 0.1 mL of MP in 1 eye. One week later, both eyes from each rabbit were enucleated, and frozen retinal sections were prepared and analyzed with light microscopy to evaluate histologic damage. RESULTS Full-thickness BV retinal penetration was observed throughout the retina in both eyes of each rabbit. All the MP-injected eyes exhibited increased antibody labeling in retinas evaluated at 6 hours, 12 hours, and 24 hours after BV injection when compared with the contralateral non-MP-injected eyes. By 3 days after BV injection, all eyes demonstrated decreased antibody labeling compared with earlier periods. At 3 days, 1 rabbit showed increased antibody labeling in the retina of the non-MP-injected eye compared with the contralateral MP-injected eye, and 2 rabbits exhibited similar antibody labeling in both eyes. When compared with control eyes, light microscopy demonstrated normal retinal histologic findings in eyes injected only with MP. CONCLUSION Increased BV retinal penetration is observed initially in eyes with an MP-induced PVD, and the mechanism is likely multifactorial. By 3 days, retinal penetration is similar in eyes with and without a PVD. Although it is difficult to directly extrapolate to humans, our study suggests that a PVD may alter the retinal penetration of BV.
Collapse
Affiliation(s)
| | - Frank J. Giblin
- Eye Research Institute, Oakland University, Rochester, Michigan
| | - Mei Cheng
- Eye Research Institute, Oakland University, Rochester, Michigan
| | | | | | | | - Alan J. Ruby
- Associated Retinal Consultants, Royal Oak, Michigan
| |
Collapse
|
32
|
Gad Elkareem AM, Willekens B, Vanhove M, Noppen B, Stassen JM, de Smet MD. Characterization of a stabilized form of microplasmin for the induction of posterior vitreous detachment. Curr Eye Res 2011; 35:909-15. [PMID: 20858112 DOI: 10.3109/02713683.2010.494819] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE To investigate the stability and safety of a diluted acidified form of microplasmin and its ability to induce a posterior vitreous detachment (PVD) following intravitreal injection in post-mortem porcine eyes. METHODS Microplasmin diluted in normal saline (NS) and balanced salt solution (BSS+) was assayed for residual activity by hydrolysis of the chromogenic substrate Glu-Phe-Lys-pNA. Residual activity on vitreous was determined by injecting aliquots of microplasmin reconstituted in balanced salt solution (BSS+) or normal saline (NS) kept at room temperature (RT) for up to 1 hr, then injected in aliquots of porcine vitreous and incubated for 2 hr at 37°C. The breakdown products were submitted to SDS Page electrophoresis and compared to determine the level of enzymatic activity. Pig eyes were incubated with graded concentrations of microplasmin 0.625, 1.25, or 2.50 mg/mL reconstituted in BBS+ or NS. Morphologic alterations and the ability to induce a PVD was assessed by light and electron microscopy. RESULTS Microplasmin's enzymatic activity in an in vitro assay in BSS+ was 70% of its baseline value after 30 min, and about 50% after 60 min at RT. The corresponding effect on degradation of vitreous gel was 60 and 40% baseline at 30 and 60 min. There was no loss of activity in the microplasmin diluted in normal saline over this time period. Dilution of acidified microplasmin in normal saline did not lead to structural changes within the retina. A dose dependent PVD was observed in eyes treated with microplasmin diluted in NS. CONCLUSIONS Acidified (stabilized) microplasmin has the same intraocular activity profile as microplasmin at a neutral pH. Better retention of activity at room temperature makes it a better candidate for use in clinical practice.
Collapse
Affiliation(s)
- Ashraf M Gad Elkareem
- Department of Ophthalmology, Academic Medical Center, University of Amsterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
33
|
Park C, Lee SH, Heo JW, Chung H. Efficacy of Autologous Plasmin-Assisted Vitrectomy for Rhegmatogenous Retinal Detachment. JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY 2011. [DOI: 10.3341/jkos.2011.52.7.825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Chaerin Park
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea
- Seoul Artificial Eye Center, Institutes for Biomedical Research, Seoul National University Hospital, Seoul, Korea
| | - Sun Ho Lee
- Department of Ophthalmology, College of Medicine, Jeju National University, Jeju, Korea
| | - Jang Won Heo
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea
- Seoul Artificial Eye Center, Institutes for Biomedical Research, Seoul National University Hospital, Seoul, Korea
| | - Hum Chung
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea
- Seoul Artificial Eye Center, Institutes for Biomedical Research, Seoul National University Hospital, Seoul, Korea
| |
Collapse
|
34
|
Joshi KK, Sahni G. Molecular cloning, expression, purification and characterization of truncated forms of human plasminogen in Pichia pastoris expression system. Process Biochem 2010. [DOI: 10.1016/j.procbio.2010.04.014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
35
|
Gad Elkareem AM, Willikens B, Stassen JM, de Smet MD. Differential vitreous dye diffusion following microplasmin or plasmin pre-treatment. Curr Eye Res 2010; 35:235-41. [PMID: 20373883 DOI: 10.3109/02713680903484259] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE Plasmin and microplasmin are related enzymes that differ mainly in size. The differential effect of plasmin and microplasmin on vitreous structure, protein degradation, and dye diffusion through porcine vitreous was evaluated. METHODS The enzymatic effect was examined using a number of approaches on fresh porcine eyes: (1) structural integrity of vitreous after a 2-hr incubation using the electron microscope (EM); (2) effect on soluble proteins within the vitreous using gel electrophoresis after incubation at various time points over a 24-hr period; (3) fluorescein dye diffusion within the vitreous cavity measured over a 1-hr period following a 2-hr incubation. The chosen enzymatic activities for plasmin 0.5 IU and microplasmin 125 microg were within the clinical range, and were chosen for equipotence. A saline control was also used in all experiments. RESULTS Significant structural changes were seen with both microplasmin and plasmin when examined by EM. Gel electrophoresis showed that microplasmin and plasmin digested the same proteins, mainly molecular weights above 50 kDa. The enzymatic effect was noticeable earlier in microplasmin-treated eyes and was more significant by the end of the incubation period. Differential fluorescein diffusion rates were seen between normal saline, plasmin, and microplasmin within the vitreous cavity. The greatest diffusion rate was seen with microplasmin and was statistically significantly higher than plasmin. CONCLUSION Microplasmin and plasmin have a similar enzymatic effect on vitreous. However, an equipotent amount of microplasmin appears to have a more extended effect on vitreous gel. This may, in part, be related to its smaller size allowing it to diffuse more readily through the vitreous matrix.
Collapse
Affiliation(s)
- Ashraf M Gad Elkareem
- Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | | | | | | |
Collapse
|
36
|
Abstract
The coagulation and fibrinolytic pathways regulate hemostasis and thrombosis, and an imbalance in these pathways may result in pathologic hemophilia or thrombosis. The plasminogen system is the primary proteolytic pathway for fibrinolysis, but also has important proteolytic functions in cell migration, extracellular matrix degradation, metalloproteinase activation, and hormone processing. Several studies have demonstrated plasmin cleavage and inactivation of several coagulation factors, suggesting plasmin may be not only be the primary fibrinolytic enzyme, but may have anticoagulant properties as well. The objective of this review is to examine both in vitro and in vivo evidence for plasmin inactivation of coagulation, and to consider whether plasmin may act as a physiological regulator of coagulation. While several studies have demonstrated strong evidence for plasmin cleavage and inactivation of coagulation factors FV, FVIII, FIX, and FX in vitro, in vivo evidence is lacking for a physiologic role for plasmin as an anticoagulant. However, inactivation of coagulation factors by plasmin may be useful as a localized anticoagulant therapy or as a combined thrombolytic and anticoagulant therapy.
Collapse
Affiliation(s)
- Jane Hoover-Plow
- Joseph J Jacobs Center for Thrombosis and Vascular Biology, Department of Cardiovascular Medicine, Lerner Research Institute Cleveland Clinic, Cleveland, Ohio 44195, USA.
| |
Collapse
|
37
|
Marder VJ, Novokhatny V. Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential. J Thromb Haemost 2010; 8:433-44. [PMID: 19943877 DOI: 10.1111/j.1538-7836.2009.03701.x] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Direct fibrinolytics are proteolytic enzymes that degrade fibrin without requiring an intermediate step of plasminogen activation. This review summarizes the current information available for five such agents, namely, plasmin (the prototypical form), three derivatives of plasmin (mini-plasmin, micro-plasmin, and delta-plasmin), and alfimeprase, a recombinant variant of a snake venom alpha-fibrinogenase, fibrolase. Biochemical attributes of molecular size, fibrin binding and inhibitor neutralization are compared. Preclinical investigations that assess the potential for thrombolytic efficacy in vitro and in animal models of vascular occlusion and for hemostatic safety in animal models of bleeding are detailed. Clinical potential has been assessed in patients with peripheral arterial and graft occlusion, acute ischemic stroke, and access catheter and hemodialysis shunt occlusions. The direct fibrinolytic agents have impressive biochemical and preclinical foundations for ultimate clinical application. However, clinical trial results for micro-plasmin and alfimeprase have not measured up to their anticipated benefit. Plasmin has thus far shown encouraging hemostatic safety, but efficacy data await completion of clinical trials. Whether direct fibrinolytics will provide clinical superiority in major thrombotic disorders over currently utilized indirect fibrinolytics such as tissue plasminogen activator remains to be determined.
Collapse
Affiliation(s)
- V J Marder
- Hematology/Medical Oncology Division, Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
| | | |
Collapse
|
38
|
Nagai N, Kawao N, Okada K, Ishida C, Okumoto K, Ueshima S, Suzuki Y, Umemura K, Matsuo O. Initial brain lesion size affects the extent of subsequent pathophysiological responses. Brain Res 2010; 1322:109-17. [DOI: 10.1016/j.brainres.2010.01.077] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2009] [Revised: 01/27/2010] [Accepted: 01/28/2010] [Indexed: 10/19/2022]
|
39
|
Holekamp NM. The vitreous gel: more than meets the eye. Am J Ophthalmol 2010; 149:32-6. [PMID: 19875090 DOI: 10.1016/j.ajo.2009.07.036] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2008] [Revised: 07/28/2009] [Accepted: 07/29/2009] [Indexed: 10/20/2022]
Abstract
PURPOSE To reexamine the role of the vitreous gel in ocular health and disease based on recent information in the ophthalmic literature. DESIGN Perspective. METHODS Review, analysis, and discussion of the implications of selected pertinent literature. RESULTS A new understanding of the vitreous gel is emerging, placing it central to many disease processes affecting the eye, including diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, nuclear sclerotic cataract, and primary open-angle glaucoma. The vitreous gel recently has been found to have the important function of oxygen regulation and distribution within the eye. As the gel undergoes age-related liquefaction or surgical removal this function is impaired. The resultant elevated intraocular oxygen tension likely proves beneficial for vascular endothelial growth factor-mediated retinal diseases. However, it may lead to oxidative stress within the eye and may contribute to disease states such as nuclear cataract and primary open-angle glaucoma. CONCLUSIONS An intact gel vitreous is central to a healthy human eye. We now understand that age-related liquefaction of the vitreous gel accompanies several age-related ocular diseases. The field of ophthalmology would benefit from future research to understand age-related vitreous liquefaction and to identify its cause.
Collapse
|
40
|
Suzuki Y. Role of Tissue-Type Plasminogen Activator in Ischemic Stroke. J Pharmacol Sci 2010; 113:203-7. [DOI: 10.1254/jphs.10r01cp] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
41
|
Chen W, Mo W, Sun K, Huang X, Zhang YL, Song HY. Microplasmin Degrades Fibronectin and Laminin at Vitreoretinal Interface and Outer Retina during Enzymatic Vitrectomy. Curr Eye Res 2009; 34:1057-64. [DOI: 10.3109/02713680903308487] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
42
|
Thijs VN, Peeters A, Vosko M, Aichner F, Schellinger PD, Schneider D, Neumann-Haefelin T, Röther J, Davalos A, Wahlgren N, Verhamme P. Randomized, Placebo-Controlled, Dose-Ranging Clinical Trial of Intravenous Microplasmin in Patients With Acute Ischemic Stroke. Stroke 2009; 40:3789-95. [DOI: 10.1161/strokeaha.109.560201] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background and Purpose—
Microplasmin is a recombinant truncated form of human plasmin. It has demonstrated efficacy in experimental animal models of stroke and tolerability in healthy volunteers. We tested the tolerability of microplasmin in patients with acute ischemic stroke.
Methods—
In a multicenter, double-blind, randomized, placebo-controlled Phase II trial, 40 patients with ischemic stroke were treated with either placebo or active drug between 3 and 12 hours after symptom onset in a dose-finding design. Ten patients received placebo, 6 patients received a total dose of 2 mg/kg, 12 patients received a total dose of 3 mg/kg, and 12 patients received a total dose of 4 mg/kg. We studied the pharmacodynamics of microplasmin and its effect on the clinical and hemodynamic parameters of the patients. MRI was used as a surrogate marker and matrix metalloproteinases serum concentrations were used as markers of neurovascular integrity. The study was underpowered to detect clinical efficacy.
Results—
Microplasmin induced reversible effects on markers of systemic thrombolysis and neutralized α
2
-antiplasmin by up to 80%. It was well tolerated with one of 30 treated patients developing a fatal symptomatic intracerebral hemorrhage. No significant effect on reperfusion rate or on clinical outcome was observed. Matrix metalloproteinase-2 levels were reduced in microplasmin-treated patients.
Conclusions—
Microplasmin was well tolerated and achieved neutralization of α
2
-antiplasmin. Further studies are warranted to determine whether microplasmin is an effective therapeutic agent for ischemic stroke.
Collapse
Affiliation(s)
- Vincent N.S. Thijs
- From the Department of Neurology (V.T.), University Hospitals Leuven, Leuven, Belgium, and the Vesalius Research Center, Katholieke Universiteit Leuven, Leuven, Belgium; UCL St Luc (A.P.), Unité neuro-vasculaire, Service de Neurologie, Bruxelles, Belgium; Abt. für Neurologie und Psychiatrie (M.V.), Allgemeines Krankenhaus der Stadt Linz, Linz, Austria; the Department of Neurology (F.A.), Wagner Jauregg Hospital, Linz, Austria; Neurologische Universitätsklinik (P.S.), Erlangen, Germany; the
| | - Andre Peeters
- From the Department of Neurology (V.T.), University Hospitals Leuven, Leuven, Belgium, and the Vesalius Research Center, Katholieke Universiteit Leuven, Leuven, Belgium; UCL St Luc (A.P.), Unité neuro-vasculaire, Service de Neurologie, Bruxelles, Belgium; Abt. für Neurologie und Psychiatrie (M.V.), Allgemeines Krankenhaus der Stadt Linz, Linz, Austria; the Department of Neurology (F.A.), Wagner Jauregg Hospital, Linz, Austria; Neurologische Universitätsklinik (P.S.), Erlangen, Germany; the
| | - Milan Vosko
- From the Department of Neurology (V.T.), University Hospitals Leuven, Leuven, Belgium, and the Vesalius Research Center, Katholieke Universiteit Leuven, Leuven, Belgium; UCL St Luc (A.P.), Unité neuro-vasculaire, Service de Neurologie, Bruxelles, Belgium; Abt. für Neurologie und Psychiatrie (M.V.), Allgemeines Krankenhaus der Stadt Linz, Linz, Austria; the Department of Neurology (F.A.), Wagner Jauregg Hospital, Linz, Austria; Neurologische Universitätsklinik (P.S.), Erlangen, Germany; the
| | - Franz Aichner
- From the Department of Neurology (V.T.), University Hospitals Leuven, Leuven, Belgium, and the Vesalius Research Center, Katholieke Universiteit Leuven, Leuven, Belgium; UCL St Luc (A.P.), Unité neuro-vasculaire, Service de Neurologie, Bruxelles, Belgium; Abt. für Neurologie und Psychiatrie (M.V.), Allgemeines Krankenhaus der Stadt Linz, Linz, Austria; the Department of Neurology (F.A.), Wagner Jauregg Hospital, Linz, Austria; Neurologische Universitätsklinik (P.S.), Erlangen, Germany; the
| | - Peter D. Schellinger
- From the Department of Neurology (V.T.), University Hospitals Leuven, Leuven, Belgium, and the Vesalius Research Center, Katholieke Universiteit Leuven, Leuven, Belgium; UCL St Luc (A.P.), Unité neuro-vasculaire, Service de Neurologie, Bruxelles, Belgium; Abt. für Neurologie und Psychiatrie (M.V.), Allgemeines Krankenhaus der Stadt Linz, Linz, Austria; the Department of Neurology (F.A.), Wagner Jauregg Hospital, Linz, Austria; Neurologische Universitätsklinik (P.S.), Erlangen, Germany; the
| | - Dietmar Schneider
- From the Department of Neurology (V.T.), University Hospitals Leuven, Leuven, Belgium, and the Vesalius Research Center, Katholieke Universiteit Leuven, Leuven, Belgium; UCL St Luc (A.P.), Unité neuro-vasculaire, Service de Neurologie, Bruxelles, Belgium; Abt. für Neurologie und Psychiatrie (M.V.), Allgemeines Krankenhaus der Stadt Linz, Linz, Austria; the Department of Neurology (F.A.), Wagner Jauregg Hospital, Linz, Austria; Neurologische Universitätsklinik (P.S.), Erlangen, Germany; the
| | - Tobias Neumann-Haefelin
- From the Department of Neurology (V.T.), University Hospitals Leuven, Leuven, Belgium, and the Vesalius Research Center, Katholieke Universiteit Leuven, Leuven, Belgium; UCL St Luc (A.P.), Unité neuro-vasculaire, Service de Neurologie, Bruxelles, Belgium; Abt. für Neurologie und Psychiatrie (M.V.), Allgemeines Krankenhaus der Stadt Linz, Linz, Austria; the Department of Neurology (F.A.), Wagner Jauregg Hospital, Linz, Austria; Neurologische Universitätsklinik (P.S.), Erlangen, Germany; the
| | - Joachim Röther
- From the Department of Neurology (V.T.), University Hospitals Leuven, Leuven, Belgium, and the Vesalius Research Center, Katholieke Universiteit Leuven, Leuven, Belgium; UCL St Luc (A.P.), Unité neuro-vasculaire, Service de Neurologie, Bruxelles, Belgium; Abt. für Neurologie und Psychiatrie (M.V.), Allgemeines Krankenhaus der Stadt Linz, Linz, Austria; the Department of Neurology (F.A.), Wagner Jauregg Hospital, Linz, Austria; Neurologische Universitätsklinik (P.S.), Erlangen, Germany; the
| | - Antoni Davalos
- From the Department of Neurology (V.T.), University Hospitals Leuven, Leuven, Belgium, and the Vesalius Research Center, Katholieke Universiteit Leuven, Leuven, Belgium; UCL St Luc (A.P.), Unité neuro-vasculaire, Service de Neurologie, Bruxelles, Belgium; Abt. für Neurologie und Psychiatrie (M.V.), Allgemeines Krankenhaus der Stadt Linz, Linz, Austria; the Department of Neurology (F.A.), Wagner Jauregg Hospital, Linz, Austria; Neurologische Universitätsklinik (P.S.), Erlangen, Germany; the
| | - Nils Wahlgren
- From the Department of Neurology (V.T.), University Hospitals Leuven, Leuven, Belgium, and the Vesalius Research Center, Katholieke Universiteit Leuven, Leuven, Belgium; UCL St Luc (A.P.), Unité neuro-vasculaire, Service de Neurologie, Bruxelles, Belgium; Abt. für Neurologie und Psychiatrie (M.V.), Allgemeines Krankenhaus der Stadt Linz, Linz, Austria; the Department of Neurology (F.A.), Wagner Jauregg Hospital, Linz, Austria; Neurologische Universitätsklinik (P.S.), Erlangen, Germany; the
| | - Peter Verhamme
- From the Department of Neurology (V.T.), University Hospitals Leuven, Leuven, Belgium, and the Vesalius Research Center, Katholieke Universiteit Leuven, Leuven, Belgium; UCL St Luc (A.P.), Unité neuro-vasculaire, Service de Neurologie, Bruxelles, Belgium; Abt. für Neurologie und Psychiatrie (M.V.), Allgemeines Krankenhaus der Stadt Linz, Linz, Austria; the Department of Neurology (F.A.), Wagner Jauregg Hospital, Linz, Austria; Neurologische Universitätsklinik (P.S.), Erlangen, Germany; the
| |
Collapse
|
43
|
Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis. J Thromb Thrombolysis 2009; 30:46-54. [DOI: 10.1007/s11239-009-0400-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
44
|
Pakola S, Cahillane G, Stassen JM, Lijnen HR, Verhamme P. Neutralization of α2-antiplasmin by microplasmin: A randomized, double-blind, placebo-controlled, ascending-dose study in healthy male volunteers. Clin Ther 2009; 31:1688-706. [DOI: 10.1016/j.clinthera.2009.08.019] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/01/2009] [Indexed: 10/20/2022]
|
45
|
|
46
|
Verhamme P, Jerome M, Goossens G, Devis J, Maleux G, Stas M. A pilot trial of microplasmin in patients with long-term venous access catheter thrombosis. J Thromb Thrombolysis 2009; 28:477-81. [DOI: 10.1007/s11239-009-0310-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2008] [Accepted: 01/30/2009] [Indexed: 11/24/2022]
|
47
|
Heidingsfeld A, Koob V, Kräuter N, Kupka J, Rastetter A, Zündorf I, Dingermann T. [Microplasmin instead of a scalpel]. PHARMAZIE IN UNSERER ZEIT 2009; 38:299-300. [PMID: 19572347 DOI: 10.1002/pauz.200990045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
|
48
|
Giblin FJ, Quiram PA, Leverenz VR, Baker RM, Dang L, Trese MT. Enzyme-induced posterior vitreous detachment in the rat produces increased lens nuclear pO2 levels. Exp Eye Res 2008; 88:286-92. [PMID: 18835558 DOI: 10.1016/j.exer.2008.09.003] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2008] [Revised: 08/26/2008] [Accepted: 09/04/2008] [Indexed: 11/28/2022]
Abstract
It has been proposed that disruption of normal vitreous humor may permit O(2) to travel more easily from the retina to the center of the lens where it may cause nuclear cataract (Barbazetto, I.A., Liang, J., Chang, S., Zheng, L., Spector, A., Dillon, J.P., 2004. Oxygen tension in the rabbit lens and vitreous before and after vitrectomy. Exp. Eye Res. 78, 917-924; Harocopos, G.J., Shui, Y.B., McKinnon, M., Holekamp, N.M., Gordon, M.O., Beebe, D.C., 2004. Importance of vitreous liquefaction in age-related cataract. Invest. Ophthalmol. Vis. Sci. 45, 77-85). In the present study, we injected enzymes intravitreally into guinea pigs (which possess an avascular retina) and rats (which possess a vascular retina) to produce either vitreous humor liquefaction plus a posterior vitreous detachment (PVD) (with use of microplasmin) or vitreous humor liquefaction only (with use of hyaluronidase), and 1-2 weeks later measured lens nuclear pO(2) levels in vivo using a platinum-based fluorophore O(2) sensor (Oxford-Optronix, Ltd.). Experiments were also conducted in which the animals were allowed to breathe 100% O(2) following intravitreal injection with either microplasmin or hyaluronidase in order to investigate possible effects on O(2) exchange within the eye. Injection of guinea pigs with either of the two enzymes produced no significant differences in lens pO(2) levels 1-2 weeks later, compared to controls. However, for the rat, injection of microplasmin produced a 68% increase in O(2) level in the center of the lens, compared to the controls (5.6mm Hg increasing to 9.4mm Hg, p<0.05), with no corresponding effect observed following similar use of hyaluronidase. Treatment of guinea pigs with microplasmin dramatically accelerated movement of O(2) across the vitreal space when the animals were later allowed to breathe 100% O(2) (for example, O(2) traveled to a location directly behind the lens 5x faster than control; p<0.01); however, the effect following treatment with hyaluronidase was significantly less. When microplasmin-injected rats breathed 100% O(2), the time required for O(2) to reach the center of the lens was 3x faster than control (0.4 min compared to 1.4 min, p<0.01). The results have implication with regard to the occurrence of age-related PVD in the human, and a possible acceleration of maturity-onset nuclear cataract. In addition, enzymatic creation of a PVD to increase the rate of O(2) exchange within the vitreal space may have potential application for treatment of retinal ischemic disease.
Collapse
Affiliation(s)
- F J Giblin
- Eye Research Institute, Oakland University, Rochester, MI 48309-4480, USA.
| | | | | | | | | | | |
Collapse
|
49
|
Rasmussen RS, Overgaard K, Pakola S, Boysen G. Effects of microplasmin on recovery in a rat embolic stroke model. Neurol Res 2008; 30:75-81. [PMID: 17588313 DOI: 10.1179/016164107x181860] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
OBJECTIVES The purpose of the present study was to examine the effects of microplasmin on behavioral performance and infarct volume after middle cerebral artery occlusion (MCAO) in rats. Some experiments support that microplasmin may have neuroprotective and thrombolytic properties. METHODS Eighty rats underwent surgery and were embolized in the right carotid territory with a fibrin-rich embolus and randomly assigned into three groups: 5 mg/kg microplasmin, 10 mg/kg microplasmin or saline (control). Groups treated with microplasmin received 50% bolus injection 10 minutes after embolization and 50% continuous infusion during the following hour. Animals from all groups were trained to obtain high baseline scores in Montoya's staircase test before embolization and were retested during 7-14 days after surgery. RESULTS When pre-maturely dead animals were excluded, no differences were observed among groups regarding infarct volumes. Furthermore, mortality was significantly lower in Group 1 than in Group 2 (p<0.05) and when performances were evaluated 7-14 days after surgery, Group 1 was significantly better than Group 2 concerning fine motor performance (p<0.05) and also achieved more normal bodyweight (p<0.05). DISCUSSION Among surviving animals, 5 mg/kg microplasmin treatment had no effect compared to saline-treated control animals; 5 mg/kg microplasmin reduced mortality and improved both behavioral rehabilitation and bodyweight compared to 10 mg/kg microplasmin treatment, while saline-treated animals did not differ from animals treated with 10 mg/kg microplasmin. Overall, these results indicate a potential beneficial effect of 5 mg/kg microplasmin treatment, while 10 mg/kg may worsen outcomes.
Collapse
Affiliation(s)
- Rune Skovgaard Rasmussen
- Copenhagen Experimental Stroke Unit, Panum Institute, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen North, Denmark.
| | | | | | | |
Collapse
|
50
|
|